|Slideshows|February 11, 2016

In This Issue: Volume 33, No 1

Stories covered in the January issue included gun violence, physician burnout and depression, mental health/HIV, young adult psychiatry, women's issues, and other topics of interest to clinicians.

Â Â

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

What's New in Psychiatric Treatment? Highlights From the 2026 Southern California Psychiatry Conference

ByJessica Walters

July 30th 2026

From Fibromyalgia to Depression: TNX-102 Sublingual Cyclobenzaprine Trials for MDD

ByGregory Sullivan, MD

July 30th 2026

TNX-102 SL in Major Depressive Disorder: Targeting Slow-Wave Sleep

ByGregory Sullivan, MD

July 29th 2026

Psyched Perspectives: Culturally Responsive Psychiatry, Insights From APA Fellow Diego Regalado, MD

ByFrank A. Clark, MD,Diego Regalado, MD

July 28th 2026

Neuroplasticity, Novel Targets, and the Future of Depression Pharmacotherapy

ByJason Kellogg, MD

July 27th 2026

Latest CME

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

In This Issue: Volume 33, No 1

Related Content

What's New in Psychiatric Treatment? Highlights From the 2026 Southern California Psychiatry Conference

From Fibromyalgia to Depression: TNX-102 Sublingual Cyclobenzaprine Trials for MDD

TNX-102 SL in Major Depressive Disorder: Targeting Slow-Wave Sleep

Psyched Perspectives: Culturally Responsive Psychiatry, Insights From APA Fellow Diego Regalado, MD

Neuroplasticity, Novel Targets, and the Future of Depression Pharmacotherapy

Latest CME

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

PET Imaging Confirms Lower Muscarinic M1 Receptor Availability in Schizophrenia

Making Sense of the New Alzheimer Treatment Landscape, With Aaron Ritter, MD

What's New in Psychiatric Treatment? Highlights From the 2026 Southern California Psychiatry Conference

Real-World and Long-Term Trial Data Show Xanomeline/Trospium Cuts Hospitalizations, Antipsychotic Burden in Schizophrenia

The Weight of Performance: Athletic Identity and Eating Disorders in Male Athletes